Our study highlights the potential importance of determining PIK3CA mutational status in early breast cancer, especially in research stetting, and by that indicates the need for further research regarding the use of PIK3CA inhibitors in the neo/adjuvant treatment strategy. The gene discussed is PIK3CA; the disease is breast cancer.